Nektar Therapeutics is a biopharmaceutical firm dedicated to identifying and advancing medical treatments for critical health conditions lacking effective therapies, serving markets across the United States and globally. Its diverse pipeline features several promising candidates: Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma. This same compound is also being investigated in Phase 2 trials for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer, in Phase 1/2A for squamous cell carcinoma of the head and neck, in Phase 1/2 for various solid tumors, and in Phase 1B for COVID-19.